[go: up one dir, main page]

WO2021222964A3 - Complexes immunogènes et leurs procédés de production et d'utilisation - Google Patents

Complexes immunogènes et leurs procédés de production et d'utilisation Download PDF

Info

Publication number
WO2021222964A3
WO2021222964A3 PCT/AT2021/060160 AT2021060160W WO2021222964A3 WO 2021222964 A3 WO2021222964 A3 WO 2021222964A3 AT 2021060160 W AT2021060160 W AT 2021060160W WO 2021222964 A3 WO2021222964 A3 WO 2021222964A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogenic complexes
producing
methods
same
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AT2021/060160
Other languages
English (en)
Other versions
WO2021222964A2 (fr
Inventor
Alireza ESLAMIAN
Martin SCHIFKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ESS Holding GmbH
Original Assignee
ESS Holding GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ESS Holding GmbH filed Critical ESS Holding GmbH
Publication of WO2021222964A2 publication Critical patent/WO2021222964A2/fr
Publication of WO2021222964A3 publication Critical patent/WO2021222964A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un procédé de formation de complexes immunogènes, en particulier un procédé de revêtement d'agents pathogènes ou de fragments de ceux-ci avec de la hMBL ou des parties de ceux-ci. En outre, l'invention concerne lesdits complexes immunogènes, des compositions pharmaceutiques comprenant lesdits complexes immunogènes, en particulier des vaccins comprenant lesdits complexes immunogènes, et l'utilisation des complexes immunogènes et des compositions pharmaceutiques.
PCT/AT2021/060160 2020-05-07 2021-05-07 Complexes immunogènes et leurs procédés de production et d'utilisation Ceased WO2021222964A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA50394/2020 2020-05-07
AT503942020 2020-05-07

Publications (2)

Publication Number Publication Date
WO2021222964A2 WO2021222964A2 (fr) 2021-11-11
WO2021222964A3 true WO2021222964A3 (fr) 2021-12-16

Family

ID=75953804

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2021/060160 Ceased WO2021222964A2 (fr) 2020-05-07 2021-05-07 Complexes immunogènes et leurs procédés de production et d'utilisation

Country Status (1)

Country Link
WO (1) WO2021222964A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002041913A1 (fr) * 2000-11-27 2002-05-30 Jens Christian Jensenius Collectines utiles comme adjuvants
WO2017143024A2 (fr) * 2016-02-16 2017-08-24 President And Fellows Of Harvard College Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002041913A1 (fr) * 2000-11-27 2002-05-30 Jens Christian Jensenius Collectines utiles comme adjuvants
WO2017143024A2 (fr) * 2016-02-16 2017-08-24 President And Fellows Of Harvard College Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VALDIMARSSON H ET AL: "RECONSTITUTION OF OPSONIZING ACTIVITY BY INFUSION OF MANNAN-BINDINGLECTIN (MBL) TO MBL-DEFICIENT HUMANS", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, vol. 48, no. 2, 1 August 1998 (1998-08-01), pages 116 - 123, XP000911946, ISSN: 0300-9475, DOI: 10.1046/J.1365-3083.1998.00396.X *

Also Published As

Publication number Publication date
WO2021222964A2 (fr) 2021-11-11

Similar Documents

Publication Publication Date Title
EP3947475A4 (fr) Compositions de vaccin contre le coronavirus, procédés et utilisations associées
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
EP4487869A3 (fr) Arn codant pour un antigène tumoral
PH12017501898A1 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2018033254A3 (fr) Arn pour la cancérothérapie
MY173299A (en) Method for preparing an enriched igg composition from plasma
ZA202310755B (en) Immunogenic composition against influenza
WO2007024941A3 (fr) Vaccin polyvalent
EP4406418A3 (fr) Masse de boisson soluble
EP4085131A4 (fr) Compositions immunogenes contre le sars-cov-2, leurs procèdes de fabrication et leur utilisation
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
GEP20247585B (en) Furoindazole derivatives
WO2019200314A3 (fr) Analogues d'hinokitiol, procédés de préparation et compositions pharmaceutiques de ceux-ci
AU2020256283A8 (en) Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof
WO2023097003A3 (fr) Compositions immunogènes et leurs utilisations
MX2019005423A (es) Conjugado proteico de polisacarido inmunogenico que comprende un polisacarido derivado de estreptococo grupo b (gbs).
WO2020146700A8 (fr) Nanoparticules lipidiques
MX2022002437A (es) Metodos para la produccion de arginasa humana recombinante 1 y sus usos.
SG11201900051UA (en) Leuconostoc mesenteroides cjlm119 strain producing reduced amount of gas, and kimchi production method using same
ZA202401405B (en) Compositions and methods for anti-pacap antibodies
ZA202000732B (en) Maturation of dendritic cells
WO2021222964A3 (fr) Complexes immunogènes et leurs procédés de production et d'utilisation
MX2015014005A (es) Complejo inmunogenico para vacunacion y metodo de obtencion.
CA3156472A1 (fr) Composition polymere
EP4400299A3 (fr) Procédés et compositions destinés à être utilisés dans des produits en bois collé

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21726033

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21726033

Country of ref document: EP

Kind code of ref document: A2